Every 10-Q that Bridgebio Pharma (BBIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BBIO filings page.
BridgeBio Pharma, Inc. reported sharply higher revenue while remaining loss‑making. For the quarter ended June 30, 2026, total revenue was $243.7 million, up from $110.6 million a year earlier, driven primarily by $222.4 million in net product revenue from Attruby/Beyonttra and expanding royalty income.
Research and development expense was $149.4 million and selling, general and administrative expense was $186.3 million, reflecting heavy investment in commercialization and late‑stage programs. Net loss attributable to common stockholders narrowed to $152.2 million (loss of $0.78 per share) from $181.9 million (loss of $0.95 per share) in the prior‑year quarter.
At June 30, 2026, BridgeBio held $677.9 million in cash and cash equivalents and $42.2 million in marketable securities, but carried $3.72 billion of total liabilities, including multiple convertible note series and $879.4 million in deferred royalty obligations, resulting in a total stockholders’ deficit of $2.50 billion. Operating activities used $268.4 million of cash in the first half, partly offset by net financing inflows, including issuance of 2033 convertible notes.
BridgeBio Pharma, Inc. reported net revenues of $194.5 million for the three months ended March 31, 2026, up from strong growth in Attruby and Beyonttra sales, including $180.6 million of net product revenue.
The company recorded a net loss attributable to common stockholders of $164.0 million, or $0.84 per share, as it continues to invest heavily in research and development and selling, general and administrative activities. Operating cash outflow was $197.3 million, but BridgeBio ended the quarter with $879.9 million in cash and cash equivalents and $60.3 million in marketable securities.
BridgeBio issued $632.5 million of 0.75% Convertible Senior Notes due 2033, using part of the proceeds to repurchase common stock and positioning itself to address existing convertible notes. The company also submitted a New Drug Application for oral BBP-418 for LGMD2I/R9 and continues late-stage development of low-dose infigratinib and encaleret.
BridgeBio Pharma (BBIO) reported Q3 2025 results as it scales commercialization of acoramidis (Attruby/Beyonttra). Total revenues were $120.7 million, driven by net product revenue $108.1 million, plus license and services revenue of $8.3 million and royalty revenue of $4.3 million. Loss from operations was $145.2 million. Net loss attributable to common stockholders was $182.7 million (basic and diluted net loss per share $0.95).
Operating expenses reflected launch build-out: research and development was $112.9 million, selling, general and administrative was $137.6 million, and restructuring, impairment and related charges were $8.8 million. Cash and cash equivalents were $642.9 million as of September 30, 2025. The balance sheet shows 2031 Notes, net, of $564.1 million, 2029 Notes, net, of $740.4 million, and 2027 Notes, net, of $546.5 million. Deferred royalty obligations, net, were $836.1 million.
Year-to-date, total revenues were $347.9 million with product revenue of $216.4 million. U.S. accounted for 89.6% of Q3 revenues. The company notes approvals for acoramidis across the U.S., EU, Japan and the UK supporting the commercial ramp.